Anusol HC ointment

Pajjiż: Ingilterra

Lingwa: Ingliż

Sors: MHRA (Medicines & Healthcare Products Regulatory Agency)

Ingredjent attiv:

Peru Balsam; Benzyl benzoate; Bismuth oxide; Bismuth subgallate; Hydrocortisone acetate; Zinc oxide

Disponibbli minn:

Church & Dwight UK Ltd

Kodiċi ATC:

C05AA01

INN (Isem Internazzjonali):

Peru Balsam; Benzyl benzoate; Bismuth oxide; Bismuth subgallate; Hydrocortisone acetate; Zinc oxide

Dożaġġ:

18.75mg/1gram ; 12.5mg/1gram ; 8.75mg/1gram ; 22.5mg/1gram ; 2.5mg/1gram ; 107.5mg/1gram

Għamla farmaċewtika:

Rectal ointment

Rotta amministrattiva:

Cutaneous; Rectal

Klassi:

No Controlled Drug Status

Tip ta 'preskrizzjoni:

Never Valid To Prescribe As A VMP

Sommarju tal-prodott:

BNF: 01070200; GTIN: 5010123713997

Karatteristiċi tal-prodott

OBJECT 1
ANUSOL HC OINTMENT
Summary of Product Characteristics Updated 13-Apr-2018 | Church &
Dwight UK Ltd
•
1. Name of the medicinal product
•
2. Qualitative and quantitative composition
•
3. Pharmaceutical form
•
4. Clinical particulars
•
4.1 Therapeutic indications
•
4.2 Posology and method of administration
•
4.3 Contraindications
•
4.4 Special warnings and precautions for use
•
4.5 Interaction with other medicinal products and other forms of
interaction
•
4.6 Fertility, pregnancy and lactation
•
4.7 Effects on ability to drive and use machines
•
4.8 Undesirable effects
•
4.9 Overdose
•
5. Pharmacological properties
•
5.1 Pharmacodynamic properties
•
5.2 Pharmacokinetic properties
•
5.3 Preclinical safety data
•
6. Pharmaceutical particulars
•
6.1 List of excipients
•
6.2 Incompatibilities
•
6.3 Shelf life
•
6.4 Special precautions for storage
•
6.5 Nature and contents of container
•
6.6 Special precautions for disposal and other handling
•
7. Marketing authorisation holder
•
8. Marketing authorisation number(s)
•
9. Date of first authorisation/renewal of the authorisation
•
10. Date of revision of the text
1. Name of the medicinal product
ANUSOL HC OINTMENT
2. Qualitative and quantitative composition
Each 100g of ointment contains:
Hydrocortisone acetate
0.25g
Bismuth subgallate
2.25g
Bismuth oxide
0.875g
Balsam Peru
1.875g
Benzyl benzoate
1.25g
Zinc oxide
10.75g
For full list of excipients, see section 6.1
3. Pharmaceutical form
Ointment.
Buff-coloured ointment.
4. Clinical particulars
4.1 Therapeutic indications
Anusol-HC Ointment is indicated for the comprehensive symptomatic
treatment of internal and external
haemorrhoids and pruritus ani.
4.2 Posology and method of administration
Anal application.
ADULTS
Apply ointment to the affected area at night, in the morning and after
each evacuation up to a maximum
of 4 applications a day. Thoroughly cleanse the affected area, dry and
apply ointment on a gauze dressing.
For internal conditions use rectal no